A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection

  • Bioorg Med Chem Lett. 2004 May 17;14(10):2613-6. doi: 10.1016/j.bmcl.2004.02.101.
David W Borhani  1 ,  David J Calderwood ,  Michael M Friedman ,  Gavin C Hirst ,  Biqin Li ,  Adelaine K W Leung ,  Brad McRae ,  Sheldon Ratnofsky ,  Kurt Ritter ,  Wendy Waegell
Affiliations
  • 1. Abbott Bioresearch Center, 100 Research Drive, Worcester, MA 01605-5314, USA.
PMID: 15109663 DOI: 10.1016/j.bmcl.2004.02.101
Abstract

We have identified the pyrazolo[3,4-d]pyrimidine A-420983 (compound 7) as a potent inhibitor of Lck. A-420983 exhibits oral efficacy in animal models of delayed-type hypersensitivity and organ transplant rejection.

Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-136622
    A-420983
    Lck Inhibitor
    target: Src